Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	15,156	4,757	7,884	8,458	9,860	9,600
Short-Term Investments	68,094	74,450	56,515	37,671	18,675	23,084
Trading Asset Securities	5,708	8,247	5,933	19,239	29,299	22,203
Cash & Short-Term Investments	88,958	87,454	70,332	65,368	57,834	54,887
Cash Growth	11.68%	24.34%	7.59%	13.03%	5.37%	-7.32%
Accounts Receivable	4,759	3,991	4,595	4,566	4,664	4,835
Other Receivables	1,579	682.88	943.86	583.11	268.43	283.39
Receivables	6,624	4,976	5,740	5,330	5,216	5,557
Inventory	4,488	4,203	4,122	4,102	3,589	3,503
Prepaid Expenses	718.99	287.27	691.85	500.5	292.5	218.67
Other Current Assets	297.58	228.19	1,044	354.58	587.81	746.72
Total Current Assets	101,087	97,148	81,929	75,655	67,519	64,913
Property, Plant & Equipment	30,929	30,463	32,937	33,638	34,057	36,602
Long-Term Investments	501.94	501.94	501.94	3,786	8,427	2
Other Intangible Assets	1,392	1,606	1,599	1,793	1,536	1,802
Long-Term Accounts Receivable	-0	0	0	0	0	0
Long-Term Deferred Tax Assets	216.96	216.96	182.29	449.3	751.56	1,395
Other Long-Term Assets	447.37	461.66	491.37	517.21	585.15	587.54
Total Assets	134,574	130,398	117,641	115,839	112,877	105,301
Accounts Payable	818.17	680.27	578.39	1,370	1,224	887.65
Accrued Expenses	1,287	481.51	489.15	443.91	470.95	496.32
Current Portion of Leases	481.73	650.28	621.14	600.78	402.89	658.65
Current Income Taxes Payable	627.24	1,404	-	1,038	814.73	-
Current Unearned Revenue	22.42	27.57	27.03	30.9	50.44	41.52
Other Current Liabilities	4,129	2,619	3,106	3,905	2,802	2,546
Total Current Liabilities	7,366	5,863	4,821	7,389	5,766	4,630
Long-Term Leases	95.39	366.66	934.17	357.79	423.49	686.44
Other Long-Term Liabilities	-0	-	-	-	0	-
Total Liabilities	7,461	6,229	5,755	7,747	6,189	5,317
Common Stock	4,700	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	12,760	12,760	12,760	12,760	12,760	12,760
Retained Earnings	132,916	130,264	118,217	114,993	109,894	102,696
Treasury Stock	-23,978	-23,978	-23,978	-23,978	-20,258	-20,258
Comprehensive Income & Other	714.32	422.69	186.4	-382.91	-408.42	86.97
Shareholders' Equity	127,113	124,168	111,885	108,092	106,687	99,985
Total Liabilities & Equity	134,574	130,398	117,641	115,839	112,877	105,301
Total Debt	577.11	1,017	1,555	958.57	826.38	1,345
Net Cash (Debt)	88,381	86,437	68,777	64,409	57,007	53,542
Net Cash Growth	12.63%	25.68%	6.78%	12.98%	6.47%	-8.16%
Net Cash Per Share	12913.76	12629.74	10049.37	9342.06	8061.43	7547.42
Filing Date Shares Outstanding	6.84	6.84	6.84	6.84	7.07	7.07
Total Common Shares Outstanding	6.84	6.84	6.84	6.84	7.07	7.09
Working Capital	93,721	91,286	77,108	68,266	61,754	60,283
Book Value Per Share	18573.12	18142.94	16348.17	15793.91	15086.68	14094.07
Tangible Book Value	125,721	122,563	110,286	106,299	105,151	98,183
Tangible Book Value Per Share	18369.77	17908.31	16114.53	15531.88	14869.49	13840.05
Land	9,696	9,696	9,765	9,765	9,765	9,784
Buildings	22,074	19,675	19,537	13,349	13,854	14,389
Machinery	25,506	25,847	25,644	7,228	8,033	9,682
Construction In Progress	128.92	385.42	338.95	993.9	247.26	95

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.